The FDA has approved Fesilty (fibrinogen, human-chmt) for the treatment of acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency (CFD), including hypo- or ...
Hepatocellular carcinoma (HCC), a leading cause of cancer-related mortality globally, exhibits a dismal five-year survival rate of only 18%. Major contributing factors to HCC include viral hepatitis ...
These include ACLY, ACC, and FASN, regulated by transcription factor SREBP1c. In HCC, SREBP1c can be overexpressed by P13K/Akt/mTOR pathway activated by CD147 and its downstream molecules, such as ...
Fibryga (R) is now approved in the U.S. for fibrinogen supplementation in both congenital and acquired fibrinogen deficiency, and is available in 1-gram and 2-gram kits, each with the nextaro (R) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback